◀ Back to IL2
CXCR3 — IL2
Text-mined interactions from Literome
Pan et al., J Immunol 2006
(Carcinoma, Renal Cell...) :
We found that systemic
IL-2 induced the expression of
CXCR3 on circulating mononuclear cells but impaired the CXCR3 ligand chemotactic gradient from plasma to tumor by increasing circulating CXCR3 ligand levels in a murine model of RCC
Reckamp et al., J Immunother 2007
(Carcinoma, Renal Cell...) :
CXCR3 is also associated with antiangiogenic effects in multiple tumors, and we hypothesized that
interleukin-2 (IL-2) treatment of patients with metastatic clear cell RCC could
augment CXCR3 levels on circulating mononuclear cells and correlate to outcome
Schmitz et al., Brain Behav Immun 2013
:
Oppositely,
CXCR3-deficiency had no protective effect after traumatic nerve injury but reduced EAE evoked hyperalgesia and was associated with reduced clinical EAE scores, a reduction of the pro-inflammatory cell infiltration and
reduced upregulation of interferon gamma and
interleukin-17 in the spinal cord